Wells Fargo lifts Cardinal Health target to $321
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Wells Fargo raised its Cardinal Health price target to $321 from $277 while keeping an Overweight rating, citing strength in the pharmaceutical and other segments. The firm also lifted its earnings per share estimates for fiscal 2027 and 2028. The move follows Cardinal Health's first-quarter fiscal 2027 results and a raised full-year profit outlook.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.